Efficacy of Antiviral Agents against the SARS-CoV-2 Omicron Subvariant BA.2.
作者信息
Takashita Emi, Kinoshita Noriko, Yamayoshi Seiya, Sakai-Tagawa Yuko, Fujisaki Seiichiro, Ito Mutsumi, Iwatsuki-Horimoto Kiyoko, Halfmann Peter, Watanabe Shinji, Maeda Kenji, Imai Masaki, Mitsuya Hiroaki, Ohmagari Norio, Takeda Makoto, Hasegawa Hideki, Kawaoka Yoshihiro
机构信息
National Institute of Infectious Diseases, Tokyo, Japan.
National Center for Global Health and Medicine, Tokyo, Japan.
出版信息
N Engl J Med. 2022 Apr 14;386(15):1475-1477. doi: 10.1056/NEJMc2201933. Epub 2022 Mar 9.
Abstract
摘要
相似文献
1
Efficacy of Antiviral Agents against the SARS-CoV-2 Omicron Subvariant BA.2.
N Engl J Med. 2022 Apr 14;386(15):1475-1477. doi: 10.1056/NEJMc2201933. Epub 2022 Mar 9.
2
Efficacy of Antiviral Agents against the Omicron Subvariant BA.2.75.
N Engl J Med. 2022 Sep 29;387(13):1236-1238. doi: 10.1056/NEJMc2209952. Epub 2022 Sep 7.
3
Characterization and antiviral susceptibility of SARS-CoV-2 Omicron BA.2.
Nature. 2022 Jul;607(7917):119-127. doi: 10.1038/s41586-022-04856-1. Epub 2022 May 16.
4
Different efficacies of neutralizing antibodies and antiviral drugs on SARS-CoV-2 Omicron subvariants, BA.1 and BA.2.
Antiviral Res. 2022 Sep;205:105372. doi: 10.1016/j.antiviral.2022.105372. Epub 2022 Jul 4.
5
Potent inhibition of diverse Omicron sublineages by SARS-CoV-2 fusion-inhibitory lipopeptides.
Antiviral Res. 2022 Dec;208:105445. doi: 10.1016/j.antiviral.2022.105445. Epub 2022 Oct 17.
6
Therapeutic antibodies and fusion inhibitors targeting the spike protein of SARS-CoV-2.
Expert Opin Ther Targets. 2021 Jun;25(6):415-421. doi: 10.1080/14728222.2020.1820482. Epub 2020 Sep 17.
7
Therapeutic efficacy of monoclonal antibodies and antivirals against SARS-CoV-2 Omicron BA.1 in Syrian hamsters.
Nat Microbiol. 2022 Aug;7(8):1252-1258. doi: 10.1038/s41564-022-01170-4. Epub 2022 Jun 15.
8
In Vitro Efficacy of Antiviral Agents against Omicron Subvariant BA.4.6.
N Engl J Med. 2022 Dec 1;387(22):2094-2097. doi: 10.1056/NEJMc2211845. Epub 2022 Nov 16.
9
SARS-CoV-2 Omicron subvariant spike N405 unlikely to rapidly deamidate.
Biochem Biophys Res Commun. 2023 Jul 23;666:61-67. doi: 10.1016/j.bbrc.2023.04.088. Epub 2023 May 2.
10
In Silico Screening of Bioactive Compounds of Representative Seaweeds to Inhibit SARS-CoV-2 ACE2-Bound Omicron B.1.1.529 Spike Protein Trimer.
Mar Drugs. 2022 Feb 17;20(2):148. doi: 10.3390/md20020148.
引用本文的文献
1
SARS-CoV-2 Pneumonia: Advances in Diagnosis and Treatment.
Microorganisms. 2025 Jul 31;13(8):1791. doi: 10.3390/microorganisms13081791.
2
Clinical Practice Guideline-Supported Administration of Monoclonal Antibody Therapy for High-Risk Patients with COVID-19: Experience of a Quaternary Care Centre.
J Assoc Med Microbiol Infect Dis Can. 2024 Sep 10;9(3):140-150. doi: 10.3138/jammi-2024-0005. eCollection 2024 Oct.
3
The pan-variant potential of light: 425 nm light inactivates SARS-CoV-2 variants of concern and non-cytotoxic doses reduce viral titers in human airway epithelial cells.
mSphere. 2025 Jun 25;10(6):e0023025. doi: 10.1128/msphere.00230-25. Epub 2025 May 28.
4
Immunogenicity of COVID-19 Vaccination in Immunocompromised Patients (Auto-COVID-VACC): Protocol for Multicenter Prospective Noninterventional Study.
JMIR Res Protoc. 2025 May 26;14:e60675. doi: 10.2196/60675.
5
Population Pharmacokinetic Modelling of Remdesivir and Its Metabolite GS-441524 in Hospitalised Patients with COVID-19.
Clin Pharmacokinet. 2025 May;64(5):743-756. doi: 10.1007/s40262-025-01496-2. Epub 2025 Apr 22.
6
Real-World Effectiveness of Sotrovimab in Patients Infected With SARS-CoV-2 Omicron Subvariant BA.2 in Western Sydney, Australia.
J Med Virol. 2025 Feb;97(2):e70235. doi: 10.1002/jmv.70235.
7
Comparative Effectiveness of Antivirals and Monoclonal Antibodies for Treating COVID-19 Patients Infected With Omicron Variant: A Systematic Review and Network Meta-Analysis.
Influenza Other Respir Viruses. 2024 Dec;18(12):e70065. doi: 10.1111/irv.70065.
8
Research progress of spike protein mutation of SARS-CoV-2 mutant strain and antibody development.
Front Immunol. 2024 Nov 18;15:1407149. doi: 10.3389/fimmu.2024.1407149. eCollection 2024.
9
Assessment of pharmacokinetics and tolerability following single-dose administration of molnupiravir in participants with hepatic or renal impairment.
Clin Transl Sci. 2024 Dec;17(12):e70073. doi: 10.1111/cts.70073.
10
A prediction of mutations in infectious viruses using artificial intelligence.
Genomics Inform. 2024 Oct 8;22(1):15. doi: 10.1186/s44342-024-00019-y.
本文引用的文献
1
Therapeutic efficacy of monoclonal antibodies and antivirals against SARS-CoV-2 Omicron BA.1 in Syrian hamsters.
Nat Microbiol. 2022 Aug;7(8):1252-1258. doi: 10.1038/s41564-022-01170-4. Epub 2022 Jun 15.
2
Efficacy of Antibodies and Antiviral Drugs against Covid-19 Omicron Variant.
N Engl J Med. 2022 Mar 10;386(10):995-998. doi: 10.1056/NEJMc2119407. Epub 2022 Jan 26.
Zotero 插件